Welcome to our dedicated page for Remsleep Holding news (Ticker: RMSL), a resource for investors and traders seeking the latest updates and insights on Remsleep Holding stock.
REMSleep Holdings, Inc. develops sleep apnea products centered on the FDA-cleared Deltawave CPAP Mask System, a nasal pillow interface for CPAP users. Company news commonly covers commercialization of Deltawave, distributor and reseller relationships, product samples for clinical and channel evaluation, and regulatory compliance topics tied to FDA clearance and 510(k) pathways.
Updates also include shareholder communications, voting matters, operating and financial results, patent-related developments for nasal ventilation technology, and corporate milestones affecting the company’s sleep apnea product pipeline.
Summary not available.
Summary not available.
REMSleep Holdings, Inc. (OTC PINK: RMSL) announced that the FDA requires additional testing for its 510K submission regarding product development. The company plans to initiate testing promptly. Furthermore, proceeds from the Reg A offering will support ongoing product development, expected patent applications, and inventory buildup pending 510K approval. The press release also contains forward-looking statements highlighting risks, including the potential inability to secure financing and regulatory challenges that could affect business outcomes.
REMSleep Holdings, Inc. (OTC PINK: RMSL) has announced that its submission K212087 has passed the acceptance review. The submission was found to contain all necessary elements for a substantive review, and a lead reviewer has been assigned to the case. The company plans to provide further updates as they become available.
This announcement follows the regulatory protocol and demonstrates the company's progress in its submission process, which may have implications for future developments.
REMSleep Holdings, Inc. (OTC PINK: RMSL) has filed a 510K submission for its DeltaWave CPAP pillows interface mask. The submission, numbered K212087, was received on July 6, 2021. This marks a significant step for the company in advancing its product offerings in the sleep treatment market. The DeltaWave Nasal Pillows System aims to enhance patient comfort and efficacy in CPAP therapy. The press release includes forward-looking statements that caution against placing undue reliance on future projections and highlights potential risks associated with financing, competition, and regulatory matters.
REMSleep Holdings, Inc. (OTC: RMSL) has engaged Empirical Technologies Corp to expedite its 510K submission, addressing frustrations with previous delays. This partnership aims to enhance the submission process, with ETC boasting a 100% success rate and approvals 20% to 40% quicker than industry norms. The company received a patent approval in April 2021 and is preparing to launch its marketing program post-510K clearance. Future products are in development, expected to be released more efficiently.